Belpointe Asset Management LLC Has $138,000 Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Belpointe Asset Management LLC lessened its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,000 shares of the medical technology company’s stock after selling 1,000 shares during the period. Belpointe Asset Management LLC’s holdings in Alphatec were worth $138,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ATEC. Barclays PLC grew its position in Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after acquiring an additional 133,653 shares during the period. Franklin Resources Inc. lifted its holdings in Alphatec by 299.3% during the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock valued at $343,000 after purchasing an additional 48,308 shares during the last quarter. State Street Corp grew its stake in Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after buying an additional 287,350 shares during the last quarter. Congress Asset Management Co. increased its holdings in shares of Alphatec by 235.4% during the fourth quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company’s stock worth $3,993,000 after buying an additional 305,296 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Alphatec by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 201,672 shares of the medical technology company’s stock valued at $1,121,000 after acquiring an additional 5,883 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Alphatec news, EVP David Sponsel sold 33,732 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at approximately $7,245,020.91. This trade represents a 4.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the transaction, the chief executive officer now directly owns 5,857,603 shares of the company’s stock, valued at $62,324,895.92. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 278,800 shares of company stock worth $3,201,469. Insiders own 22.80% of the company’s stock.

Alphatec Trading Up 3.2 %

Shares of NASDAQ ATEC opened at $10.56 on Friday. The company’s 50 day simple moving average is $10.38 and its 200 day simple moving average is $9.42. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.79. The firm has a market capitalization of $1.52 billion, a P/E ratio of -8.25 and a beta of 1.20.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ATEC shares. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Monday. Piper Sandler boosted their target price on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Finally, StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.